NIRS-IVUSimaging can help identify high-risk plaques that can lead to adverse outcomes
Results from PROSPECT II reported at TCT Connect
NEW YORK – October 14, 2020 – New data from the PROSPECT II study shows that NIRS-IVUS intracoronary imaging can help identify angiographically non-obstructive lesions with high-risk characteristics for future adverse cardiac outcomes.
Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
Acute coronary syndromes most often arise from rupture and thrombosis of lipid-rich atherosclerotic plaques that develop in the setting of systemic inflammation. In the PROSPECT study, a large plaque burden or small lumen area assessed by intravascular ultrasound (IVUS) identified angiographically mild lesions at increased risk to cause future coronary events. While lipid-rich fibroatheromas identified by IVUS can be predictive, plaque interpretation with this technique is not as precise.
Lipid content may be more accurately measured by near-infrared spectroscopy (NIRS). Recent studies have suggested that lipid-rich plaques detected by intracoronary NIRS imaging are associated with adverse outcomes. Identifying these “vulnerable” plaques before they progress may help to inform pharmacologic or other strategies to stabilize the plaque.
PROSPECT II was an investigator-sponsored multicenter, prospective, natural history study conducted at 16 centers in Sweden, Denmark and Norway to validate the use of NIRS and IVUS imaging in identifying non-obstructive lipid-rich plaques that are prone to cause future cardiac events.
After successful treatment of all flow-limiting lesions in patients with recent myocardial infarction, imaging of all three coronary arteries was performed with a combination NIRS-IVUS catheter. The lipid content of “non-culprit” lesions was assessed by NIRS, and IVUS assessment was also performed. The primary outcome was the covariate-adjusted rate of major adverse cardiac events (the composite of cardiac death, myocardial infarction, unstable angina, or progressive angina) adjudicated to have arisen from non-culprit lesions. The relationship between plaques with high lipid content, large plaque burden, and small lumen areas and patient-level and lesion-level events were tested hierarchically.
A total of 3,629 untreated non-culprit lesions were prospectively characterized in 898 patients with myocardial infarction. Adverse events within four years occurred in 13.2% of patients, with a total of 8.0% of events arising from untreated non-culprit lesions with mean baseline diameter stenosis 46.9%. The presence of highly lipidic lesions was an independent predictor of patient-level non-culprit events (adjusted OR 2.27; 95% CI 1.25-4.13) and lesion-specific events (adjusted OR 7.83; 95% CI 4.12-14.89). Large plaque burden and small lumen areas were also independent predictors of adverse events.
“In PROSPECT II, lipid-rich plaques, as detected by NIRS, identified angiographically mild non-flow limiting lesions responsible for future coronary events,” said David Erlinge, MD, PhD. Dr. Erlinge is Professor, Department of Cardiology, Clinical Sciences, Lund University at Skane University Hospital in Sweden.
“High lipid content, along with large plaque burden and small lumen area, may be added as prognostic indices of vulnerable plaques that put patients at risk for adverse outcomes. Further studies prospectively utilizing this information are warranted to improve outcomes for high-risk patients with coronary artery disease.”
The PROSPECT II trial was funded by research grants from Abbott Vascular, Infraredx and The Medicines Company. Dr. Erlinge reported the following disclosures: speaker fees from Amgen, AstraZeneca, Bayer, and Chiesi; and fees for Advisory Boards from Bayer, Boehringer Ingelheim, and Sanofi.
The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 32nd year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.
For more information, visit http://www.